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Abstract: Members of the classic type of transient receptor potential channels (TRPC) represent important molecules in-
volved in hormonal signal transduction. TRPC3/6/7 channels are of particular interest as they are components of phos-
pholipase C driven signalling pathways. Upon receptor-activation, G-protein-mediated stimulation of phospholipase C re-
sults in breakdown of phosphatidylinositides leading to increased intracellular diacylglycerol and inositol-trisphosphate 
levels. Diacylglycerol activates protein kinase C, but more interestingly diacylglycerol directly activates TRPC2/3/6/7 
channels. Molecular cloning, expression and characterization of TRP channels enabled reassignment of traditional inhibi-
tors of receptor-dependent calcium entry such as SKF-96365 and 2-APB as blockers of TRPC3/6/7 and several members 
of non-classic TRP channels. Furthermore, several enzyme inhibitors have also been identified as TRP channel blockers, 
such as ACA, a phospholipase A2 inhibitor, and W-7, a calmodulin antagonist. Finally, the naturally occurring secondary 
plant compound hyperforin has been identified as TRPC6-selective drug, providing an exciting proof of concept that it is 
possible to generate TRPC-selective channel modulators. The description of Pyr3 as the first TRPC3-selective inhibitor 
shows that not only nature but also man is able to generate TRP-selective modulators. The review sheds lights on the cur-
rent knowledge and historical  development of pharmacological modulators of TRPC3/6/7. Our analysis  indicates that 
Pyr3 and hyperforin provide promising core structures  for the development of new, selective and more potent modulators 
of  TRPC3/6/7 activity. 
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INTRODUCTION 
  With completion of the human genome project, more 
than 1200 G-protein coupled receptors have been identified 
ranging from well-known receptors to orphan receptors. 
Among them, a large group of receptors is activated by vola-
tile compounds. The great diversity of ligands and receptors 
is integrated on the cellular level by a small number of cellu-
lar signalling cascades. The integration is mediated by G-
proteins transducing ligand-dependent changes of receptor 
conformation into subsequent signalling pathways. In the 
context of calcium-permeable ion channels, hormonal signal-
ling cascades integrated by the G-proteins of the Gq family 
and/or G-protein -subunits are of particular interest. Their 
activation results in a phospholipase C-mediated breakdown 
of phosphatidylinositides leading to the formation of inositol 
1,4,5-trisphosphate and diacylglycerol (Fig. (1)). Inositol 
1,4,5-trisphosphate induces calcium release from intracellu-
lar stores, whereas diacylglycerol directly activates mammal-
ian classic transient receptor potential (TRPC) channels 
(TRPC2, TRPC3, TRPC6 and TRPC7) in a protein kinase C-
independent manner [1-3]. 
  With respect to the fly origin of prototypic TRP channels, 
it is interesting to note that diacylglycerol is not able to   
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Fig. (1). Signalling cascade leading to TRPC3/6/7 activation. Hor-
monal stimulation of G-protein coupled receptor (GPCR) activates 
phospholipase C  isoforms  (PLC  ) via a G-protein dependent 
mechanism. Phospholipase C activity results in the breakdown of 
phosphatidylinositides (PIP2) leading to the formation of inositol 
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). Inositol 1,4,5-
trisphosphate as ligand of inositol 1,4,5-trisphosphate receptors 
located at the endoplasmic reticulum induce calcium release from 
intracellular stores, whereas DAG activates mammalian TRPC2, 
TRPC3, TRPC6 and TRPC7 channels. In contrast to the mammal-
ian signalling cascade, Drosophila TRPL and TRP are activated by 
poly-unsaturated fatty acids (PUFA) generated by phospholipase A2 
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directly stimulate the Drosophila TRPC members (TRP, 
TRPL, TRP). Instead, Drosophila TRPL and TRP are acti-
vated by phospholipase A2-dependent poly-unsaturated fatty 
acids [4, 5]. The activation is directly caused by poly-
unsaturated fatty acids like arachidonic acids (AA), but not 
downstream metabolites of AA which can be blocked by 
eicosatetraynoic acid. Eicosatetraynoic acid is routinely used 
as inhibitor of metabolic arachidonic acid pathways like 
lipoxygenases, cyclooxygenases and cytochrome P450 iso-
enzymes. 
  In pharmacological research focussed on human diseases, 
TRPC2 in mostly ignored. TRPC2 is a pseudogene in   
human. Functional TRPC2 is found only in rodents, with 
TRPC2 involved in the pheromone signalling. Based on the 
broad expression profile of TRPC3 and TRPC6 being de-
tected in many neuronal, epithelial and vascular smooth 
muscle cells [6], it is not surprising that both proteins are 
involved in a great variety of functions [7, 8]. In contrast, 
expression of TRPC7 is restricted to a few cell types and the 
physiological role of TRPC7 is still unclear [9]. This review 
will focus on pharmacological modulation of mammalian 
TRPC3/6/7. We will discuss a broad number of drugs that 
interfere with TRPC3/6/7 activity and function. 
INORGANIC BROAD RANGE TRP CHANNEL 
BLOCKERS 
  Since the first functional characterization of TRP chan-
nels, small molecules were introduced as tools for pharma-
cological modulation. For calcium-permeable ion channels, 
barium or strontium ions were initially used as divalent 
cations to study the selectivity and function of the new pro-
teins [10, 11]. Barium entry measurements allowed to char-
acterize heterologously expressed TRPC3 in DT40 and its 
contribution to receptor-dependent and independent signal-
ling pathways [11]. On the other hand, TRPC6 were simi-
larly characterized in vascular smooth muscle cells [10]. 
While divalent cations are able to permeate through the pores 
of non-selective TRPC3/6/7 cation channels, the trivalent 
cations gadolinium and lanthanum ions have been found to 
block TRPC3/6/7-mediated calcium entry [12-15]. The half-
maximal concentration of lanthanum chloride necessary for 
TRPC3 inhibition was 4 M, whereas more than 50 M of 
lanthanum chloride was needed to block TRPC6 [12, 14]. 
These data prompted the usage of trivalent cations as tools to 
characterize TRPC channel-dependent signalling pathways 
in various cell types. 
ORGANIC BROAD RANGE TRP CHANNEL BLOC-
KERS 
  Organic synthetic blockers have been recognized to inter-
fere with receptor-dependent and store-operated calcium 
entry mechanisms [16, 17]. SKF-96365, 1-{[3-(4-methoxy-
phenyl)propoxy]-4-methoxyphenethyl}-1H-imidazole hydro-
chloride, (Fig. (2)) is an inhibitor of receptor-mediated as 
well as store-operated calcium entry mechanisms [16, 17]. 
Initially introduced as inhibitor of receptor-mediated calcium 
entry, SKF-96365 blocked ADP-induced calcium entry in 
platelets, neutrophils and endothelial cells with IC50 values 
of ~10 M [18]. Usage of SKF-96365 allowed to discrimi-
nate between ATP- and bradykinin-induced calcium entry 
mechanisms in PC-12 cells and to characterize ATP- and N-
formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP)-
stimulated cation currents in HL-60 cells [19, 20]. Due to the 
initial characterization of SKF-96365 as blocker of receptor-
induced calcium entry in mammals, attempts have been 
made to introduce SKF-96365 as selective blocker of diacyl-
glycerol-regulated TRP channels, including TRPC3, TRPC6 
[2, 12, 21]. Accordingly, Boulay et al. observed a complete 
block of heterologously expressed TRPC6 using 100 M 
SKF-96365; the same concentration was effective in block-
ing endogenously expressed TRPC3 in human myometrial 
cells [12, 21]. 
  A quite different history is obvious for 2-APB,   
2-aminoethoxydiphenyl borate. Initially used as low cost 
alternative to the naturally occurring xestospongin C, 2-APB 
was introduced as blocker of inositol 1,4,5-trisphosphate 
receptors and used in this context for the characterization of 
store-operated calcium entry mechanisms [22]. In those early 
days, nearly all TRP channels have been characterized as 
store-operated calcium entry channels mostly based on data 
 
 
 
 
 
 
Fig. (2). Chemical structures of broad range TRP channel blocker. SKF-96365: 1-{[3-(4-methoxyphenyl)propoxy]-4-methoxyphenethyl}-
1H-imidazole hydrochloride; 2-APB: 2-aminoethoxydiphenyl borate; ACA: N-(p-amylcinnamoyl)anthranilic acid; ML-9: [1-(5-
Chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine hydrochloride]; W-7: N-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide 
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showing channel inhibition by 2-APB. However, it soon be-
came clear that 2-APB targets more molecular structures 
than initially thought. Besides blocking all members of the 
TRPC and TRPM family [23-27], 2-APB stimulates TRPV-
mediated calcium entry [28-30]. The discovery of stromal 
interactions molecules (STIM) (such as STIM1 and STIM2) 
and plasma membrane channels Orai1, Orai2 and Orai3 (also 
known as CRACM1, CRACM2 and CRACM3, respectively) 
has revealed novel molecular targets of 2-APB [31]. STIM1 
and STIM2 represent the calcium sensors of the endoplasmic 
reticulum interacting and regulating Orai (or CRACM) 
channels. 2-APB interacts with CRACM channels; however, 
the interactions seem to be complex. CRACM1 and 
CRACM2 are blocked by 2-APB, whereas 2-APB activates a 
current in STIM1 and CRACM3 coexpressing cells [32-34]. 
  Therefore, the molecular identification, cloning and func-
tional characterisation of a great variety of ion channels en-
abled the identification of SKF-96365 and 2-APB as broad-
range TRP (and CRACM) channel blockers. In contrast to 
them, other chemical structures initially described as specific 
inhibitors of enzymes and proteins have seen a revival as 
they were identified as TRP channel blockers. One of these 
molecules is N-(p-amylcinnamoyl) anthranilic acid (ACA). 
In order to interfere with the AA-dependent modulation of 
TRPM2, we characterized several compounds described as 
phospholipase A2 inhibitors. Together with arachidonyl 
trifluoromethyl ketone and p-bromophenacyl bromide, ACA 
was initially identified as a promising selective compound. 
However, subsequent detailed studies analyzed the complete 
blocking profile of ACA. It was found that ACA blocks 
TRPM2 and closely related TRPM8. ACA also inhibits 
TRPC3, TRPC6 and TRPV1 activity [35, 36]. 
  Another example of a compound with a much broader 
spectrum profile than initially speculated is ML-9, [1-(5-
Chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine 
hydrochloride]. ML-9 has been initially identified as TRPC6 
inhibitor [37]. In order to test whether TRPC6 activity is 
modulated by myosin light chain kinase (MLCK), Shi et al. 
tested several compounds described for inhibition of myosin 
light chain kinase [37]. Whereas MLCK-inhibiting peptides 
and other tools were found to be ineffective, Shi et al. dem-
onstrated that ML-9 is as potent blocker of TRPC6. ML-9 
has also been described as calmodulin-dependent MLCK 
inhibitor; it is structurally related to W-7, a compound de-
scribed to interfere with calmodulin (Fig. (2)). In order to 
provide molecular insights into the pharmacology of TRPC6 
channels, the effects of ML-9 and W-7 were studied on 
TRPC6 activated by hyperforin by FLIPR experiments Fig. 
(3). Using this approach, we tested several other structurally 
related compounds to get a first view on the structure-
function relationships of TRPC6. Fig. (3) shows that all 
those compounds blocked hyperforin-induced TRPC6-
mediated calcium entry with similar potencies. Curious to 
see whether W-7 is a TRPC6 or TRPC channel selective 
drug, we studied its inhibitory effect on TRPC6, TRPM2, 
TRPM3, TRPV4 and Drosophila TRP stimulated by either 
hyperforin, hydrogen peroxide, pregnenolone sulphate, 4-
phorbol-didecanoate or eicosatetraynoic acid, respectively 
(Fig. (4)). The IC50 values of TRPC6, TRPM2, TRPM3, 
TRPV4, Drosophila TRP inhibition were 28 M, 26 M,  
 
15 M, 65 M, 5 M, respectively. The data also show that 
ML-9 and related compounds may act as calmodulin-
inhibitors in cell free experiments. However, in cell-based 
experiments it is unlikely that the compounds can cross the 
plasma membrane due to their sulphonamide structure pro-
viding good water solubility. Overall, these data demonstrate 
that many “established” pharmacological tools in TRP chan-
nel research have to be critically re-evaluated to draw correct 
conclusions about the identity of TRP channels involved in 
biological processes and the pharmacology of the channels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Concentration-response relationship of ML-9 and W-7 
related compounds on hyperforin-induced, TRPC6-mediated fluo-
rescence changes. A) The chemical structures of the tested com-
pound is shown. ML-9: 1-(5-Chloronaphthalene-1-sulfonyl)-1H-
hexahydro-1,4-diazepine; W-7: N-(6-Aminohexyl)-5-chloro-1-nap-
hthalenesulfonamide; W-5: N-(6-Aminohexyl)-1-naphthalene-
sulfonamide; W-7 isomer: N-(6-Aminohexyl)-5-chloro-2-naphth-
alenesulfonamide; J-8: (N-8-Aminooctyl)-5-iodo-1-naphthalene-
sulfonamide; W-7 decyl: N-(6-Aminodecyl)-5-chloro-1-naphtha-
lenesulphonamide. B) Data from a representative experiment show 
the effect of ML-9, W-7, W-7 decyl, W-7 isomer, W-5 and J-8 on 
calcium entry in TRPC6-expressing cells upon hyperforin stimula-
tion. Calcium entry was measured using FLIPR
Tetra and data ana-
lysed as described in Jörs et al. [5]. The data were calculated from 
one experiment of at least three experiments performed in quadru-
plicates per concentration and TRP channel. The concentration-
response curves determined by calcium imaging showed a quite 
distinct inhibition profile. The IC50 values of ML-9, W-7, W-7 iso-
mer, W-7 decyl W-5, J-8 were 36 M, 26 M, 35 M, 29 M,  
20 M, 85 M, respectively. 
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Fig. (4). Concentration-dependent inhibition of TRPC6-, TRPM2-, 
TRPM3-, TRPV4- and TRP-mediated calcium entry by W-7. Fluo-
rescence of TRPC6-, TRPM2-, TRPM3-, TRPV4- and  TRP-
expressing, fluo-4-loaded cells in were stimulated with hyperforin 
(10  M), hydrogen peroxide (5 mM), pregnenolone sulphate   
(35 M), 4-phorbol-didecanoate (5 M) and eicosatretranoic acid 
(20  M), respectively. Calcium entry was measured using 
FLIPR
Tetra and data analysed as described in Jörs et al. [5]. The data 
were calculated from one experiment of at least three experiments 
performed in quadruplicates per concentration and TRP channel. 
The concentration-response curves determined by calcium imaging 
showed a quite distinct inhibition profile. The IC50 values to block 
TRPC6, TRPM2, TRPM3, TRPV4, Drosophila TRP were 28 M, 
26 M, 15 M, 65 M, 5 M, respectively. 
 
SELECTIVE MODULATORS OF TRPC3/6/7 CHAN-
NELS 
  The discovery of hyperforin as selective TRPC6 channel 
modulator is exciting by the fact that modulation of TRP 
channels by secondary plant compounds is not restricted to 
TRP channels involved in thermo sensation and pain [38]. 
The discovery of hyperforin as selective TRPC6 channel 
modulator was initially surprising. Since hyperforin is the 
first naturally occurring modulator of channels of the TRPC 
family, there is hope that further TRPC subfamily modula-
tors can be discovered. Hyperforin, a bicyclic polyprenylated 
acylphloroglucinol derivate, is the main active ingredient of 
St. John´s wort extract, which is widely used as the herbal 
alternative to treat depression. In 2002, 12% of US adults 
reported to use St. John’s wort extract within the last 12 
months [39]. Several recent clinical trials [40-42] and Coch-
rane meta analysis confirm the clinical efficacy and good 
tolerability of St. John’s wort for depression [43]. The effect 
of classic, synthetic antidepressants is based on inhibition of 
neuronal uptake of serotonin, dopamine and norepinephrine 
by a direct block of the transport proteins (Fig. (5)). The neu-
ronal uptake of serotonin, dopamine and noradrenaline by 
neurotransmitter transporters are frequently dependent on 
electrochemical gradients, such as Na
+ gradients, across the 
plasma membrane. In contrast to classic, synthetic anti-
depressants, hyperforin reduces monoamine uptake by ele-
vating the intracellular sodium concentration and subsequent 
elimination of the sodium gradient as required for neuro-
transmitter transporter function [44, 45]. The effect is medi-
ated by direct activation of TRPC6 [38]. By direct hyper-
forin-channel interaction, sodium and calcium permeate the 
pore of TRPC6 see Fig. (5). Increase in intracellular sodium 
counterbalances the sodium gradient across the plasma 
membrane, thereby, indirectly inhibiting neurotransmitter 
transporters. The acute increase in neurotransmitter in the 
synaptic cleft is followed by calcium-dependent neuronal 
differentiation see Fig. (5). Hyperforin likely integrates inhi-
bition of neurotransmitter uptake and neurotrophic property 
by specific activation of TRPC6. 
  In traditional herbal medicine, St. John´s wort is used for 
treatment of depression [43] and can be used for topical 
treatment of superficial wounds, burns and dermatitis [46]. 
The skin barrier is formed by keratinocytes. During their 
passive transport to the skin surface, change in morphology 
and expression profile is indicative for keratinocyte differen-
tiation, until they finally scale up in danders. In cell culture 
studies, keratinocytes differentiation can be induced by in-
creasing extracellular calcium concentration leading to acti-
vation of the calcium receptor (CaR). In addition, increases 
in extracellular calcium concentration enhance the calcium 
gradient across the plasma membrane resulting passively in 
increased intracellular calcium concentration. Several publi-
cations have described endogenous TRPC expression pro-
files in keratinocytes. Cai et al. detected TRPC1, TRPC5, 
TRPC6 and TRPC7 in gingival keratinocytes [47], whereas 
Beck et al. showed expression of TRPC1, TRPC4, TRPC5 
and TRPC7 in HaCaT keratinocytes [48]. TRPC1 as well as 
TRPC4 have been implicated in the CaR triggered elevation 
of [Ca
2+]i [47, 48]. Furthermore, the expression profile of 
TRPC channels is dynamically regulated. Calcium-induced 
differentiation of gingival keratinocytes results in elevated 
expression of TRPC1, TRPC5, TRPC6 and TRPC7 [47]. 
Treatment of keratinocytes with betulin, a triterpene ex-
tracted from the outer bark of birch (betulae cortex), results 
in increased TRPC6 expression [49]. In agreement with these 
data, we recently showed that TRPC6 is functionally ex-
pressed in keratinocytes and contributes to differentiation 
processes. Accordingly, inactivation of TRPC6 translation 
decreases calcium-dependent differentiation monitored by 
keratin 1 and keratin 10 expression [50]. Furthermore, the 
experimental set up allowed us to show that TRPC6 repre-
sents the molecular target for triggering differentiation proc-
esses in keratinocytes [50]. In summary, TRPC6 seems to 
serve as the molecular target for hyperforin-induced neuronal 
and keratinocyte differentiation. 
  In clinical practice, the use of hyperforin is handicapped 
by its capacity to induce the cytochrome P450 (CYP) system 
leading to increased expression of CYP3A and CYP2C [51, 
52]. The induction of CYP3A and CYP2C is critical as these 
enzymes metabolise up to 50% and 20% of several therapeu-
tically used drugs, respectively. In accordance, hyperforin 
affects the metabolism and corresponding plasma concentra-
tions of at least 70% of the therapeutically used drugs [51, 
52]. On the other hand, CYP2C enzymes are important in the 
generation of biologically active molecules such as epoxyei-
cosatrienoic acids (EETs) and hydroxyeicosatrienoic acids 
(HEETs), which originate from arachidonic acid in both liver 
and extrahepatic tissues such as kidney, heart, aorta, and 
blood vessels [51]. EETs regulate vasodilation [53] which is 
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with St. John´s wort extracts systemic blood pressure and 
heart rate seem to be unchanged [54]. The stable blood pres-
sure is amazing as TRPC6 is expressed in vascular smooth 
muscle cells and obviously involved in regulation of vascular 
tone [10, 55-58]. From this data, one would expect that under 
St. John´s wort therapy systemic blood pressure would rise 
due to increased arterial blood vessel constriction induced by 
increased TRPC6-mediated calcium entry. This may occur 
shortly after beginning of therapy, whereas in steady state 
phase this effect might be compensated by increased EET 
production via CYP2C induction. Block of voltage-gated 
calcium channels may play an additional role [59, 60]. The 
long-term effects of hyperforin therapy on kidney function 
are unclear since gain-of-function mutations of TRPC6 have 
been implicated in familial focal segmental glomerulosclero-
sis [61-64]. However, the mechanism of this effect is rather 
unclear since not all mutations showed increased channel 
function. 
  Hyperforin is a polyprenylated bicyclic acylphlorogluci-
nol derivative. Extensive chemical degradation and derivati-
sation studies have established its cage like structure 
(Beerhues, 2006). Exposed to light and oxygen, hyperforin is 
very unstable, which may additionally contributes to differ-
ences in hyperforin content in St. John´s wort extract leading 
to the comment “The association of country of origin and 
precision with effects sizes complicates the interpretation.” 
in the Cochrane report [43]. Based on the core structure of 
hyperforin, the phloroglucinol structure, we characterized 
several phloroglucinol derivatives [65]. Symmetric 2,4-
diacylphloroglucinol derivative have been identified as ac-
tive compounds stimulating heterologously as well as 
endogenously expressed TRPC6 [65]. Despite massive sim-
plification and reduction in complexity, the symmetric 2,4-
diacylphloroglucinol derivatives showed a comparable activ-
ity profile tested in several test systems such as transmitter 
uptake, neurotrophic assay, and TRPC6 activity. Notably, 
chemical modification of structures provided by nature gen-
erally result in loss of selectivity and activity. However, in 
the case of hyperforin, the symmetric 2,4-diacylphloro-
glucinol derivatives preserved their potency in activation of 
TRPC6 channels, whereas closely related TRPC3 and 
TRPC7 channels remained unaffected by these drugs [65]. 
  The structure of the symmetric 2,4-diacylphloroglucinol 
derivatives (Hyp derivatives) is also interesting in the con-
text of other TRPC-selective pharmacological tools (Fig. 
(6)). Recently, Kiyonaka et al. described Pyr3 as selective  
 
 
 
 
 
 
Fig. (6). Comparison of the chemical structure of Hyp1 and Pyr-PP. 
 
TRPC3 inhibitor [66]. The compound Pyr3 is based on the 
precursor BTP2, described as inhibitor of store-operated cal-
cium release-activated calcium (CRAC) channels essential 
for T-cell activation and proliferation [67]. In contrast to 
BTP2, Pyr3 is a selective inhibitor of TRPC3 channels leav-
 
 
 
 
 
 
 
 
Fig. (5). Mechanistic model of the hyperforin-dependent antidepressive effect. Within the neurotransmitter circuit of release and uptake, 
hyperforin and classic, synthetic antidepressants attack different targets resulting in reduced presysnaptic uptake of neurotransmitter and 
increase concentration of neurotransmitter in the synaptic cleft. Whereas classic synthetic antidepressants directly block the neurotransmitter 
transporters, hyperforin activates TRPC6 channel in proximity of the neurotransmitter transporters. TRPC6 is a non-selective cation channel 
enabling the permeation of sodium and calcium. Sodium entry mediated by TRPC6 activation reduced the sodium gradient across the plasma 
membrane. As the activity of the neurotransmitter transporters depends on the electrochemical sodium gradient, TRPC6 activity indirectly 
inhibits neurotransmitter uptake. On the other hand, TRPC6-mediated calcium entry may trigger calcium-dependent differentiation processes 
responsible for changes in neuronal plasticity. 40    Current Pharmaceutical Biotechnology, 2011, Vol. 12, No. 1  Harteneck and Gollasch 
ing the activity of other TRPC channel members unchanged 
[66]. For cross linking experiments, a Pyr3 derivative, Pyr-
PP, was developed. Pyr-PP was shown to be activated and 
chemically linked to TRPC3 by UV-light activation [66]. 
  In summary, beside several pharmacological tools, which 
can be classified as broad-range TRP channel blocker, Pyr3, 
hyperforin and the Hyp derivatives represent the first TRPC-
selective modulators. While Pyr3 selectively blocks TRPC3 
channels, hyperforin and the Hyp-derivative stimulate 
TRPC6 channels. Both core structures provide the basis for 
further development of new, selective and more potent 
modulators of TRPC3/6/7 activity. 
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